Literature DB >> 14999697

BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis.

Christiane Pauli-Magnus1, Reinhold Kerb, Karin Fattinger, Thomas Lang, Birgit Anwald, Gerd A Kullak-Ublick, Ulrich Beuers, Peter J Meier.   

Abstract

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are characterized by a cholestatic pattern of liver damage, also observed in hereditary or acquired dysfunction of the canalicular membrane transporters bile salt export pump (BSEP, ABCB11) and multidrug resistance protein type 3 (MDR3, ABCB4). Controversy exists whether a genetically determined dysfunction of BSEP and MDR3 plays a pathogenic role in PBC and PSC. Therefore, 149 healthy Caucasian control individuals (control group) were compared to 76 PBC and 46 PSC patients with respect to genetic variations in BSEP and MDR3. Sequencing spanned approximately 10,000 bp including promoter and coding regions as well as 50-350 bp of flanking intronic regions. In all, 46 and 45 variants were identified in BSEP and MDR3, respectively. No differences between the groups were detected either in the total number of variants (BSEP: control group: 37, PBC: 37, PSC: 31; and MDR3: control group: 35; PBC: 32, PSC: 30), or in the allele frequency of the common variable sites. Furthermore, there were no significant differences in haplotype distribution and linkage disequilibrium. In conclusion, this study provides an analysis of BSEP and MDR3 variant segregation and haplotype structure in a Caucasian population. Although an impact of rare variants on BSEP and MDR3 function cannot be ruled out, our data do not support a strong role of BSEP and MDR3 genetic variations in the pathogenesis of PBC and PSC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999697     DOI: 10.1002/hep.20159

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

Review 1.  Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein).

Authors:  Ronald P J Oude Elferink; Coen C Paulusma
Journal:  Pflugers Arch       Date:  2006-04-19       Impact factor: 3.657

Review 2.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

Review 3.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

4.  Early Diagnosis of ABCB11 Spectrum Liver Disorders by Next Generation Sequencing.

Authors:  Su Jeong Lee; Jung Eun Kim; Byung-Ho Choe; An Na Seo; Han-Ik Bae; Su-Kyeong Hwang
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2017-06-28

Review 5.  The bile salt export pump: molecular properties, function and regulation.

Authors:  Marco Arrese; Meenakshisundaram Ananthanarayanan
Journal:  Pflugers Arch       Date:  2004-07-24       Impact factor: 3.657

Review 6.  Bile acid transporters in health and disease.

Authors:  A Kosters; S J Karpen
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

7.  Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress.

Authors:  Irina M Bochkis; Nir E Rubins; Peter White; Emma E Furth; Joshua R Friedman; Klaus H Kaestner
Journal:  Nat Med       Date:  2008-07-27       Impact factor: 53.440

Review 8.  Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.

Authors:  Michael Trauner; Peter Fickert; Emina Halilbasic; Tarek Moustafa
Journal:  Wien Med Wochenschr       Date:  2008

9.  Genomic variants associated with primary biliary cirrhosis.

Authors:  Carlo Selmi; Natalie J Torok; Andrea Affronti; M Eric Gershwin
Journal:  Genome Med       Date:  2010-01-26       Impact factor: 11.117

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.